Article Details
Retrieved on: 2025-04-15 02:21:06
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche is gaining access to petrelintide, a potentially best-in-class amylin analog, paying Copenhagen-based Zealand Pharma $1.65 billion up front ...
Article found on: www.nature.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here